Live Registration: Analysis of the new features of the 2025 edition of the Chinese Pharmacopoeia
The Chinese Pharmacopoeia is an important technical code based on the research and development, registration, production, distribution and supervision of the Chinese pharmaceutical industry and has legal status. The revision and continuous improvement of the Pharmacopoeia is not only the main work of the Pharmacopoeia Committee, but also a symbolic event for the sustainable development of Chinese pharmaceuticals. The 2025 edition of the Chinese Pharmacopoeia is under revision, and the content of the new edition will inevitably bring new changes in many areas. On September 26, the "Interpretation of Pharmaceutical Administration" column of the Intellectual Medicine Research Society was specially launched "Analysis of New Developments in the 2025 Edition of Chinese Pharmacopoeia" At the live conference, Mr. Ding Enfeng, a senior technical expert in GMP and pharmaceutical regulation, was invited to give us an understanding of the revision progress of the 2025 edition of the Pharmacopoeia in various important sections, helping pharmaceutical companies quickly grasp the development trends of the…
Explore the latest exhibition information and industry trends at ASAP Expo Magazine. Your one-stop platform, bringing together global exhibition highlights, industry trends and in-depth analysis, to help companies accurately connect with the market and seize business opportunities.
